Ocular Therapeutix reports Q4 2021 DEXTENZA revenue $12.2M, up 77% YoY; net loss $3.9M

OCULAR THERAPEUTIX, INC

2021-FY EPS reported -$0.98 revenue$43,522,000

DEXTENZA net product revenue $12.2M in Q4, +77% vs Q4 2020; full year $43.5M vs $17.4M.
Net loss $(3.9)M ($0.05 basic EPS) includes $15.9M non-cash gain; full year net loss $(6.6)M.
Cash $164.2M at Dec 31, 2021; expects to fund operations through 2023.
OTX-TKI (wet AMD) US Phase 1 fully enrolled; interim data expected H2 2022.
OTX-DED (dry eye) Phase 2 met primary endpoint; positive top-line data Dec 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.